Department of Nutrition and Dietetics.
Department of Critical Care, Guy's and St Thomas' NHS Foundation Trust.
Curr Opin Clin Nutr Metab Care. 2024 Nov 1;27(6):479-485. doi: 10.1097/MCO.0000000000001066. Epub 2024 Aug 1.
Critical care nutrition guidelines recommend provision of higher protein doses than recommended in health. These recommendations have been predominately based on lower quality evidence and physiological rationale that greater protein doses may attenuate the significant muscle loss observed in critically ill patients. This review discusses the mechanistic action of protein in the critically ill, details results from recent trials on health outcomes, discusses considerations for interpretation of trial results, and provides an overview of future directions.
Two recent large clinical trials have investigated different protein doses and the effect on clinical outcome. Important findings revealed potential harm in certain sub-groups of patients. This harm must be balanced with the potential for beneficial effects on muscle mass and physical function given that two recent systematic reviews with meta-analyses demonstrated attenuation of muscle loss with higher protein doses. Utilizing biological markers such as urea: creatinine ratio or urea levels may prove useful in monitoring harm from higher protein doses.
Future research should focus on prospectively investigating biological signatures of harm as well as taking into the consideration elements that will likely enhance the effectiveness of protein dose.
重症监护营养指南建议提供高于健康推荐量的蛋白质剂量。这些建议主要基于较低质量的证据和生理学原理,即更大剂量的蛋白质可能会减轻重症患者观察到的显著肌肉损失。本文讨论了蛋白质在重症患者中的作用机制,详细介绍了近期关于健康结果的试验结果,讨论了试验结果解释的注意事项,并概述了未来的发展方向。
最近两项大型临床试验研究了不同的蛋白质剂量及其对临床结果的影响。重要的发现揭示了某些亚组患者可能存在潜在危害。这种危害必须与更高蛋白质剂量对肌肉质量和身体功能的潜在有益影响相平衡,因为最近的两项系统评价和荟萃分析表明,更高蛋白质剂量可减轻肌肉损失。利用生物标志物,如尿素:肌酐比值或尿素水平,可能有助于监测更高蛋白质剂量的危害。
未来的研究应集中于前瞻性地调查危害的生物学特征,并考虑可能增强蛋白质剂量有效性的因素。